%20(7).jpg)
.jpg)
Perzea Launch by Hetero Healthcare and Enzene Supports India’s Vision of Accessible Cancer Care
Hyderabad (Telangana) [India] : Reinforcing the Government of India’s mission to provide equitable healthcare, Hetero Healthcare Limited, in partnership with Enzene Biosciences, has launched Perzea, its most affordable biosimilar Pertuzumab for HER2-positive breast cancer. This initiative underlines the critical need for advanced cancer treatment accessibility in the country.Closing the Treatment GapPertuzumab, a globally accepted monoclonal antibody therapy, significantly improves outcomes when used with trastuzumab and...
L
Lifestyle
NEWS CARD
“Perzea Launch by Hetero Healthcare and Enzene Supports India’s Vision of Accessible Cancer Care”
Read more on
dailyoutluk.com
26 Sep 2025
Hyderabad (Telangana) [India] : Reinforcing the Government of India’s mission to provide equitable healthcare, Hetero Healthcare Limited, in partnership with Enzene Biosciences, has launched Perzea, its most affordable biosimilar Pertuzumab for HER2-positive breast cancer. This initiative underlines the critical need for advanced cancer treatment accessibility in the country.
Closing the Treatment Gap
Pertuzumab, a globally accepted monoclonal antibody therapy, significantly improves outcomes when used with trastuzumab and chemotherapy. However, for many Indian patients, high costs have been a deterrent. Perzea bridges this divide, offering patients a more affordable yet effective option.
